Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Jurgens, M S ^a   Welsing, P M J ^a   Jacobs, J W G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Disease modifying anti rheumatic drugs; Meta analyses; Overview; Rheumatoid arthritis; Tight control; Treat to target

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TRIAMCINOLONE;

ARTICLE; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; HUMANS; PATIENT CARE PLANNING; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84870265734     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. SCOTT DL, WOLFE F, HUIZINGA TW: Rheumatoid arthritis. Lancet 2010;376:1094-108.
2. CONAGHAN PO, GREEN MJ, EMERY P: Established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999;13:561-75.
3. PINCUS T, SOKRA T, RAUTIAINEN H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-19.
4. CHOI HK, HERNAN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
5. VAN HULST LT, HULSCHER ME, VAN RIEL PL: Achieving tight control in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1729-31.
6. RESMAN-TARGOFF BH, CICERO MP: Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care 2010;16:S249-58.
7. WILSKE KR, HEALEY LA: Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
8. KATZ WA: Challenging the pyramid. A new look at therapeutic approaches for rheumatoid arthritis. Patient selection. J Rheumatol 1990;25(Suppl.):39-41.
9. VAN DER HEIDE A, JACOBS JW, BIJLSMA JW et al.: The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
10. JURGENS MS, JACOBS JW, BIJLSMA JW: The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol 2011;25:523-33.
11. SOKKA T, ENVALDS M, PINCUS T: Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008;18:228-39.
12. BARKER MF, JACOBS JW, WELSING PM et al.: Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010;69:1849-52.
13. KIRWAN JR, BIJLSMA JW, BOERS M, SHEA BJ: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007: CD006356.
14. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
15. SCHIPPER LG, VAN HULST LT, GROL R, VAN RIEL PL, HULSCHER ME, FRANSEN J: Metaanalysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010;49:2154-64.
16. BARKER MF, JACOBS JW, VERSTAPPEN SM, BIJLSMA JW: Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66(Suppl. 3):iii56-60.
17. BAKRER MF, JACOBS JW, WELSING PM et al.: Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. A randomized trial. Ann Intern Med 2012;156:329-39.
18. VERSTAPPEN SM, JACOBS JW, VAN DER VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
19. FELSON DT, SMOLEN JS, WELLS G et al.: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
20. SMOLEN JS, ALETAHA D: What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006;24:S-7-13.
21. WAREFIELD RJ, D'AGOSTINO MA, NAREDO E et al.: After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis 2012;71:799-803.
22. SCHOELS M, KNEVEL R, ALETAHA D et al.: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43.
23. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
25. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK, RERSTENS PJ et al.: DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
26. SCHIPPER LG, VERMEER M, RUPER HH et al.: A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2011.
27. VAN TUYL LH, LEMS WF, VOSRUYL AE et al.: Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574-7.
28. MORELAND LW, O'DELL JR, PAULUS HE et al.: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis Rheum 2012.
29. MONTECUCCO C, TODOERTI M, SARELLARIOU G, SCIRE CA, CAPORALI R: Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012;14:R112.
30. TAR PP, RIGBY WF, RUBBERT-ROTH A et al.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
31. KAVANAUGH A, FLEISCHMANN RM, EMERY P et al.: Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2012.
32. MOTTONEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
33. SAUNDERS SA, CAPELL HA, STIRLING A et al.: Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008;58:1310-7.
34. SOUBRIER M, PUECHAL X, SIBILIA J et al.: Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009;48:1429-34.
35. LANDEWÉ R, GEUSENS P, BOERS M et al.: Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1390-9.
36. WOLFE F, PINCUS T: The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. J Rheumatol 2001;28:1817-24.
37. SMOLEN JS, ALETAHA D, BIJLSMA JW el al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
38. VAN DER HEIDE A, JACOBS JW, DINANT HJ, BIJLSMA JW: The impact of endpoint measures in rheumatoid arthritis clinical trials. Semin Arthritis Rheum 1992;21:287-94.
39. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(Suppl. 31):S179-85.
40. GAUJOUX-VIALA C, MOUTERDE G, BAILLET A et al.: Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 2012;79:149-55.
41. BARKER MF, JACOBS JW, KRUIZE AA et al.: reclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet. Ann Rheum Dis 2011.
42. LANDEWE R, VAN DER HEIJDE D, VAN DER LINDEN S, BOERS M: Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637-41.
43. TON E, BARKER MF, VERSTAPPEN SM et al.: Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol 2012;39:22-7.
44. LEE YC, CUI J, LU B et al.: Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011;13:R83.
45. WALLIN H, VAN VOLLENHOVEN R, ERNESTA M, INGEMAR F, PETERSSON KA, KRISTINA FORSLIND S, REZAEI JOHAN BRATT PGH: In early RA, patients with a good initial response to MTX monotherapy have excellent clinical outcomes over two years of therapy, but radiological progression is not completely prevented. Arthritis Rheum 2010;62:1393.
46. REZAEI H, VAN VOLLENHOVEN R, FORSLIND K et al.: Radiological progression in patients with early RA and a good clinical response to MTX monotherapy: Predictors and clinical implications. Arthritis Rheum 2010;62:1392.
47. SOKKA T, PINCUS T: Rheumatoid arthritis: strategy more important than agent. Lancet 2009;374:430-2.